로딩 중…
지수 로딩 중…
인트론바이오
048530· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩2,860-2.39%
2026-09-18
Financials
Valuation Metrics
인트론바이오's Market Cap is ₩884B. At end of 2025 it was ₩1004B. Ranked #1352 of 2,421 in KR market (top 56%), #756 of 1,640 on KOSDAQ (top 46%), #147 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 64%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 88.35B KRW | KR#1,352/2,421 Sec#147/231 |
| Revenue | 7.25B KRW | KR#2,313/2,421 Sec#183/231 |
| Net Income | -10.34B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 68.37B KRW | KR#2,027/2,421 Sec#169/231 |
| Net Assets | 62.17B KRW | KR#1,765/2,421 Sec#149/231 |
| Employees | 70 | KR#1,873/2,421 Sec#161/231 |
| Value | ||
| P/B | 1.42x | KR#1,739/2,421 Sec#121/231 |
| P/S | 12.19x | KR#2,293/2,421 Sec#168/231 |
| Profitability | ||
| ROE | -16.62% | KR#2,054/2,421 Sec#159/231 |
| ROA | -15.12% | KR#2,193/2,421 Sec#168/231 |
| Op. Margin | -109.18% | KR#2,309/2,421 Sec#177/231 |
| Revenue Growth | 40.90% | KR#274/2,421 Sec#32/231 |
| Financial Health | ||
| Debt Ratio | 9.97% | KR#143/2,421 Sec#30/231 |
| Total Debt | 4.80B KRW | KR#1,802/2,421 Sec#172/231 |
| Cash | 26.30B KRW | KR#1,082/2,421 Sec#74/231 |
| Current Ratio | 9.56x | KR#105/2,421 Sec#24/231 |
| Dividend | ||
| Div. Yield | 7.24% | KR#106/2,421 Sec#1/231 |
| Div. Growth | 0.00% | KR—/2,421 Sec—/231 |
| Performance | ||
| 1Y Return | -28.50% | KR#1,518/2,421 Sec#118/231 |
| 1M Return | 7.92% | KR#576/2,421 Sec#38/231 |
| From 52W High | -59.20% | KR#1,832/2,421 Sec#139/231 |
| 1Y MDD | -64.96% | KR#1,745/2,421 Sec#146/231 |
| Trading | ||
| Volume | 53,398 shares | KR#1,097/2,421 Sec#108/231 |
| Trading Value | 153.2M KRW | KR#1,367/2,421 Sec#141/231 |
| Foreign Own. | 2.32% | KR#1,516/2,421 Sec#142/231 |
| Per Share | ||
| EPS | -335 KRW | KR—/2,421 Sec—/231 |
| BPS | 2,013 KRW | KR#2,065/2,421 Sec#172/231 |
Company Info
동사는 1999년 설립된 바이오 벤처기업으로 2011년 코스닥에 상장함. 신약파트는 박테리오파지 플랫폼 기술 기반 itLysin과 IMPA™ 기술분야로 신약개발을 추진하고, DR파트는 PCR 및 qPCR 기반 진단제품 개발·생산으로 수익을 창출함. 플랫폼으로 내성균 치료제, 백신개발, 면역치료제 영역까지 확장하며 'from SUPERBUG to IMMUNE' 개념으로 글로벌 기술을 선도하고 있음. 인트론바이오는 1999년에 설립되었으며 경기도 성남시에 본사를 두고 있습니다.